VIDEO: Combined mirvetixumab, bevacizumab yield positive results in ovarian cancer
Click Here to Manage Email Alerts
In this video, Janos L. Tanyi, MD, PhD, assistant professor in the department of gynecologic oncology at the University of Pennsylvania, spoke with Healio about a study evaluating the use of mirvetuximab soravtansine for recurrent ovarian cancer.
In the study, presented at the ASCO Annual Meeting, women with platinum-resistant and platinum-agnostic ovarian cancer received mirvetuximab (IMGN853, ImmunoGen) combined with bevacizumab (Avastin, Genentech) on day 1 of a 21-day cycle.
“This drug was already extensively evaluated, but not in this combination,” Tanyi said.
The overall response rate was 64%, with a mean duration of response of 11.8 months, and mean progression-free survival was 10.3 months, according to the abstract.
“These results encourage the clinicians to use this combination in recurrent primary peritoneal, ovarian and fallopian tube cancer in the future,” Tanyi said.
Collapse
O’Malley DM, et al. Abstract 5504. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts